ClearPoint Neuro Announces Agreement with NE Scientific to Integrate Gene Therapy Infusion Coverage Tool into ClearPoint Maestro® Brain ModelGlobeNewsWire • 04/18/23
ClearPoint Neuro Announces ANVISA Approval of Neuro Navigation Portfolio in BrazilGlobeNewsWire • 04/13/23
ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBSGlobeNewsWire • 04/11/23
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery PlatformGlobeNewsWire • 03/28/23
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2022 Revenue Results March 1, 2023GlobeNewsWire • 02/15/23
ClearPoint Neuro Is A 'Buy' Based On Growing Revenues And Decreasing Cash BurnSeeking Alpha • 01/30/23
ClearPoint Neuro Announces First Patient Enrolled in Glioblastoma Trial Using ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital in SwedenGlobeNewsWire • 12/12/22
ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy SystemGlobeNewsWire • 09/23/22
ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating OfficerGlobeNewsWire • 09/20/22
ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC DeficiencyGlobeNewsWire • 07/21/22
ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal EpilepsyGlobeNewsWire • 06/29/22
ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?Zacks Investment Research • 06/27/22